Summary of the PPTA/FDA Liaison Meeting (November 8, 2023)

PDMPs — which are derived from human plasma from healthy donors — are essential for around 300,000 European patients who rely on these therapies to treat a variety of rare, chronic, and potentially life-threatening conditions, which are often genetic in origin. Without these treatments, many patients might not survive or would have a substantially diminished quality of life. In addition, plasma-derived medicines are also used in everyday treatment, such as supportive treatment in trauma cases, liver disease, cardiac surgery, and in some cases, pregnancy complications.

By clicking Accept all cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.